Impact of dose escalation on colostomy-free survival and treatment outcome in squamous cell anal carcinoma.

ABSTRACT:

Purpose

Primary radiochemotherapy (RCT) constitutes the standard of care for early- and advanced-stage anal carcinoma. This retrospective study investigates the impact of dose escalation on colostomy-free survival (CFS), overall survival (OS), locoregional control (LRC), progression-free survival (PFS), and acute and late toxicities in patients with squamous cell anal cancer.

Methods

Considered were the outcomes of 87 patients with anal cancer treated with radiation/RCT between May 2004 and January 2020 at our institution. Toxicities were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE version 5.0).

Results

The 87 patients received treatment with a median boost of 63 Gy to the primary tumor. With a median follow-up of 32 months, the 3‑

SUBMITTER: Untiedt S 

PROVIDER: S-EPMC10361861 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature